EGT-101 is under clinical development by Esteve Pharmaceuticals and currently in Phase II for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ). According to GlobalData, Phase II drugs for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the EGT-101 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EGT-101 overview
EGT-101 is under development for the treatment of Sanfilippo syndrome type A. It is administered through intracerebroventricular route. The therapeutic candidate utilizes adeno-associated virus vector serotype 9 (AAV9) to deliver the human sulfoglucosamine sulfohydrolase gene (AAV9-sulfamidase). It is developed based on NAV technology.
See Also:
Esteve Pharmaceuticals overview
Esteve Pharmaceuticals (Esteve) researches, develops, and markets prescription and generic pharmaceuticals. The company’s product portfolio encompasses innovative prescription drugs, over the counter (OTC) pharmaceuticals and generic drugs. It offers drugs in central nervous system, infection, respiratory, cardiovascular, cancer, primary care, and other therapeutic areas. Esteve also provides customized contract manufacturing services of active pharmaceutical ingredients (APIs) and advanced intermediates for the global pharmaceutical industry. The company markets its products to pharmaceutical companies, healthcare facilities and other customers through licensing agreements and distributors. It operates subsidiaries and production centers in Europe, the Americas, Africa, Oceania, and Asia. Esteve is headquartered in Barcelona, Spain.
For a complete picture of EGT-101’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
